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Abstract: 
Catechol-based inhibitors of ERCC1-XPF endonuclease activity were identified from a high-
throughput screen. Exploration of the structure-activity relationships within this series 
yielded compound 13, which displayed an ERCC1-XPF IC50 of 0.6 µM, high selectivity 
against FEN-1 and DNase I and activity in nucleotide excision repair, cisplatin enhancement 
and H2AX assays in A375 melanoma cells. Screening of fragments as potential alternatives 
to the catechol group revealed that 3-hydroxypyridones are able to inhibit ERCC1-XPF with 
high ligand efficiency, and elaboration of the hit gave compounds 36 and 37 which showed 
promising ERCC1-XPF IC50 values of <10 µM. 
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Platinum-based chemotherapeutics such as cisplatin result in several forms of DNA damage, 
however their effectiveness can be limited by efficient DNA repair processes. The ERCC1-
XPF complex, formed from the heterodimerization of excision-repair cross complementation 
group 1 (ERCC1) and xeroderma pigmentosum F (XPF), has structure-specific endonuclease 
activity and plays an essential role in the removal of platinum-DNA adducts by nucleotide 
excision repair (NER).1 It is also involved in interstrand crosslink repair (ICR) and there is 
evidence that it is a good target for intervention in melanoma, ovarian, lung and other 
cancers.1 Inhibition of ERCC1-XPF activity therefore represents an approach to potentially 
enhance the effectiveness of chemotherapeutic agents such as cisplatin, however very few 
inhibitors have been reported in the literature.2 
 
We sought to identify novel inhibitors of ERCC1-XPF using a high-throughput fluorescence-
based in vitro endonuclease assay3 and one of the hits obtained was compound 1 (Figure 1) 
with an IC50 value of approximately 30 µM and modest ligand efficiency. The catechol motif 
is present in known nuclease inhibitors4 and although the dibromo-substitution and hydrazone 
motif were considered undesirable, 1 showed good selectivity for ERCC1-XPF in counter-
screen assays against the nucleases FEN-1 and DNase I.3 We therefore sought to explore 
whether it was possible to design out the unwanted features and gain additional potency while 
retaining good selectivity for ERCC1-XPF. Testing of initial analogues showed that the 
catechol group was required for inhibitory activity since mono- or di-methylation led to 
complete loss of activity. Catechols are known to be effective binders of metal ions, in 
particular magnesium and manganese; the activity of ERCC1-XPF is metal-dependent and 
the presence of Mn2+ is required for substrate turnover in the biochemical assay. It was 
therefore our hypothesis that they could inhibit ERCC1-XPF via binding to a metal ion at the 
endonuclease active site.  
 
1
ERCC1-XPF IC50 = 33 μM
Ligand efficiency = 0.25
FEN-1 IC50 > 100 μM
DNase I IC50 > 100 μM
 
 
Figure 1. Initial hit compound 1 
 
Synthesis and testing of early analogues showed that the removal of the two bromine atoms 
and methyl group (Table 1, compound 2) and replacing the hydrazone with an amide (3) were 
all well tolerated, and this led to an improvement in potency and ligand efficiency while 
retaining selectivity against FEN-1 and DNase I. Variation of the linker lengths on the right-
hand-side portion of the amide core suggested that benzyl was preferred (4).  
 
 
Table 1. Activity and selectivity data from analogues of initial hit 
 
Compound Structure ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µM 
DNase I 
IC50/ µM 
2 
 
2.0 >100 >100 
3 
 
15.2 >100 >100 
4 
 
0.9 >100 >100 
5 
 
1.6 >100 >100 
 
 
With the benzylic catechol in place, a range of groups on the left-hand side portion of the 
molecule were explored (Table 2), with synthetic access through amide coupling. Replacing 
the aniline NH in 4 with carbon (6) or oxygen (7) both led to reductions in potency, and 
shortening the linker also led to losses in potency (8, 9). However, the introduction of 
additional substituents allowed potency to be regained, such as methyl (10), 4-chloro (11) or 
2-chloro (12). The 2,4-dichloro variant (13) was the most potent compound at 0.6 µM.  The 
4-methoxy compound (14) was less potent than the 4-chloro, and the larger cyclohexyl 
variant (15) was relatively well tolerated. Smaller alkyl groups such as isopropyl (16) and 
cyclopentyl (17) were weak, although the cyclohexylmethyl (18) displayed an IC50 value of 
just over 1 micromolar. The introduction of more polar or larger groups (19-23) did not lead 
to potency improvements relative to 13. 
 
 
 
Table 2. Activity and selectivity data from left-hand side variations  
 
Compound R1 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µMa 
DNase I 
IC50/ µMa 
6 
 
7.3 >100 >100 
7 
 
12.1 >100 >100 
8 
 
13.3 >100 >100 
9 
 
24.5 >100 >100 
10 
 
1.8 >100 nt 
11 
 
1.0 >100 >100 
12 
 
0.80 >100 >100 
13 
 
0.63 >100 >100 
14 
 
2.6 nt nt 
15 
 
1.6 >100 nt 
16 
 
24.0 nt nt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a nt = not tested. 
 
Modifications to the right-hand side portion were explored (Table 3) via amide coupling with 
the 2,4-dichlorobenzyl group fixed: cyclisation (24) or N-methylation of the amide (25) did 
not significantly affect potency. Halogen substituents were added to the catechol ring to 
explore the effect of modifying the steric and electronic properties (26, 27) including tuning 
the pKa of the catechol OH groups, and although this was tolerated it did not improve 
potency. 
 
 
Table 3. Activity and selectivity data from right-hand side variations 
Compound NR1R2 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µM 
DNase I 
IC50/ µM 
24 
 
1.0 >100 >100 
25 
 
0.8 >100 >100 
26 
 
1.6 >100 >100 
17 
 
24.6 >100 >100 
18 
 
1.4 >100 >100 
19 
 
4.0 nt nt 
20 
 
25.6 nt nt 
21 
 
7.9 >100 >100 
22 
 
>100 nt >100 
23 
 
5.8 >100 >100 
27 
 
1.1 >100 >100 
 
Alterations to the amide core were investigated (Table 4): the sulfonamide 28 showed 
reduced potency in comparison with 13, whereas the reverse amide 29 was equipotent to the 
parent amide. The ureas (30, 31) and oxadiazole variants (32, 33) also showed weaker 
potency compared to 13. 
 
 
Table 4. Activity and selectivity data from variations to amide core 
 
Compound Structure ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µM 
DNase I 
IC50/ µM 
28 
 
2.9 >100 >100 
29 
 
0.74 >100 >100 
30 
 
4.8 >100 >100 
31 
 
4.1 >100 >100 
32 
 
12.2 >100 >100 
33 
 
7.8 >100 >100 
 
Next, the potential for modifying the catechol motif was explored; as the catechol represents 
a liability, especially with respect to oxidation, replacement was desirable. Previous data 
suggested that it would be necessary for an alternative group to have good metal-binding 
capability, so in order to identify catechol variants we screened a number of fragments with 
metal-binding capability in our biochemical assay, with the intention that these could then be 
merged with the existing left-hand side portion. This identified 5-bromo-3-hydroxypyridone 
34 as a fragment with a promising IC50 of 24 µM and high ligand efficiency (Figure 2); this 
fragment has recently been shown to inhibit the activity of an influenza endonuclease with a 
similar level of potency and bind through a metal-based interaction.5,6 
 
ERCC1-XPF IC50 ~ 100 μM 
3534
ERCC1-XPF IC50 = 24 μM 
Ligand efficiency = 0.70  
 
Figure 2. 5-Bromo-3-hydroxypyridone fragment 34 and merged compound 35   
 
However, when it was merged with the left-hand side portion of compound 13 to give 35, this 
compound showed very weak activity against ERCC1-XPF, suggesting that the fragment 
might be binding in a different way to the catechol. Instead we therefore sought to exploit the 
fragment by substituting at the available positions, and due to the relative lack of structural 
knowledge around the protein binding site a systematic approach was employed. Firstly, 
replacing the bromine with a 4-fluorophenyl group (Table 5, 36) gave a gain in potency to 
less than 10 µM and the 3-pyrazole substituted variant 37 showed an IC50 of approximately 5 
µM. A wider range of R3 variants were investigated and selected examples are shown in 
Table 5; although none showed improved potency compared to 37, three other variants were 
within 3-fold (38-40). Substitution at the alternative vectors R1, R2 or R4 appeared to be 
poorly tolerated (41-43).  
  
 
Table 5. Activity and selectivity data from 3-hydroxypyridone fragment substitution 
 
Compound R1 R2 R3 R4 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µMa 
DNase I 
IC50/ µMa 
36 H H 
 
H 8.7 >100 >100 
37 H H 
 
H 5.2 >100 >100 
38 H H 
 
H 13.1 >100 >100 
39 H H 
 
H 13.5 >100 >100 
40 H H 
 
H 14.6 >100 >100 
41 Me H 
 
H >100 nt nt 
42 H 
 
H H 55.2 nt nt 
43 H H H 
 
>100 nt nt 
 
a nt = not tested. 
 
 
Compounds 13 and 36 were profiled in ADMET assays (Figure 3). Compound 13 showed 
relatively short mouse and human microsomal half-lives and acceptable permeability, 
whereas 36 showed a long half-life; both compounds were not toxic to Hep-G2 cells up to a 
compound concentration of 10 µM. 
 
Compound Log D Cytotox Hep-G2 v-50/ µM 
MLM 
t1/2/ mins 
HLM 
t1/2/ mins 
PAMPA 
Papp/ nms-1 
13 2.7 >10 23 28 39 
36 2.0 >10 >400 >400 44 
 
Figure 3. Measured in vitro ADMET profiles for compounds 13 and 36 
 
 
Although the catechols and hydroxypyridones showed selectivity for ERCC1-XPF over FEN-
1 and DNase I, catechols in particular can show PAINS effects7,8 and interfere with assays 
through non-specific mechanisms; therefore it was important to demonstrate binding to target 
using a biophysical method. The interaction of compounds 13 and 36 with ERCC1-XPF was 
examined by surface plasmon resonance (SPR). Compound 13 showed a KD of ~30 µM, 
weaker than the biochemical IC50, with relatively slow binding kinetics (Figure 4). By 
contrast, the hydroxypyridone 36 showed fast binding kinetics and a KD of 3.5 µM, in good 
agreement with the biochemical IC50. Neither compound showed binding to a control protein 
included in the study. 
 
 
Figure 4. SPR sensorgrams for compounds 13 (left) and 36 (right) 
 
 
Compound 13 was profiled in three cell-based assays using A375 melanoma cells to measure 
1) direct nucleotide excision repair (NER) using a recombinant GFP reporter assay,3,9 2) 
potentiation of cisplatin induced cell toxicity10 and 3) immunofluorescence detection of 
H2AX, a marker of DNA damage.11 
Firstly, in the NER assay, repair of UV damaged pEGFP plasmid was monitored following 
treatment with compound for 24 hours at concentrations of up to 60 µM. Compound 13 
showed inhibition of NER with an IC50 of 15.6 µM (Figure 5).9 
                           
                     
Figure 5. Compound 13 NER in A375 melanoma cell line transfected with UV damaged pEGFP and a 
luciferase reporter plasmid (pGL3) to control for transfection efficiency.  The fluorescence read out generated as 
the pEGFP plasmid is repaired is normalized to both luciferase levels and readings for undamaged DNA to 
generate the DNA Repair Index.  Inhibition of NER is detected at higher concentrations of compound, IC50=15.6 
µM.  
Secondly, compound 13 was profiled in a cisplatin combination assay10 (Figure 6a). The 
compound alone showed a reduction in cell number at 4.96 and 10 µM (Figure 6b), however 
at compound concentrations where no toxicity was observed with compound only, there was 
an enhancement of cisplatin activity up to 1.5-fold (PF50) as shown in the table in Figure 6.  
 
 
 
 
Figure 6. Cisplatin potentiation assay dose-response curves for compound 13. A375 cells were treated in 96-
well plates and cell count measured using an InCell 2000 high content imager (GE Healthcare). Curves show 
activity of cisplatin alone (0µM compound) and then in combination with the indicated concentrations of 
compound. A shift in cisplatin potency was observed with increasing concentration of compound up to 2.03-fold 
with 10 µM compound (a). The compound alone showed some cell death at the 2 highest concentrations, 4.96 
and 10µM (b). Results are from 4 separate experiments and the error bars are SD.  
 
Thirdly, compounds were assayed in a γH2AX foci assay which is a marker of DNA repair11 
(Figure 7). A delay in repair of γH2AX foci was observed after 6 hours post treatment of cells 
with cisplatin in combination with compound 13 as indicated by a right shift towards higher 
numbers of foci per cell. 
 
 
 
 
Figure 7.  Compound 13 activity in a γH2AX foci imaging assay. γH2AX foci count in A375 cells pretreated 
with compound for 1h, exposed to 5 µM cisplatin for 1h and continued exposure to compound at 10 µM for 6h. 
Levels of γH2AX were quantified by immunofluorescence using a specific antibody (Millipore) and results 
analysed on an InCell 2000 High Content Imager (GE Healthcare). Relative cumulative frequency plots were 
used in order to visualize the shift in the response to cisplatin and compound treatment. Compound 13 causes a 
delay in DNA repair as illustrated by the rightward shift of the curve showing that cells contain larger numbers 
of foci.  The combined treatment of cisplatin and compound 13 is significantly more than cisplatin alone 
(p=0.0012 by Sum of Squares F test of the EC50).  Results are from 2 representative experiments (triplicate tests 
in each) and the error bars are SEM. 
 
 
In summary, we have shown that compounds containing a catechol or a 3-hydroxypyridone 
motif inhibited ERCC1-XPF with sub-micromolar or low micromolar potency in the 
endonuclease biochemical assay and displayed high selectivity over the other two nucleases 
tested. Exemplars from both series showed binding to ERCC1-XPF by SPR, and the leading 
example compound 13 showed inhibition of DNA repair in A375 melanoma cells across 
three assay formats. Further studies are required to understand the binding mode and cellular 
mechanism of action of these compounds. 
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